GLP1R and metabolic dysfunction-associated steatohepatitis: Taken together, these direct effects of GLP-1 agonist on hepatocytes, Kupffer cells, and hepatic stellate cells, as well as the improvement in glucose homeostasis, could have contributed to the prevention of NASH progression and hepatocarcinogenesis in the current study.